NCT05919485 · RECRUITING

The Effects of Specific tDCS on Cognition in MCI

This trial is testing whether transcranial direct current stimulation, or tDCS, a non-invasive brain stimulation technique, can slow or reduce cognitive decline in people with mild cognitive impairment, either from early Alzheimer's-related causes or Parkinson's disease. Mild electrical current is delivered to specific brain regions over two weeks. This is a Phase NA, meaning it is a controlled feasibility and effectiveness study, not a standard drug approval phase. Results are not yet proven.

You may qualify if

  • Providing an informed consent;
  • Literate and between 45-80 years of age;
  • 60 females and 60 males;
  • Diagnosed with PD based on criteria suggested by UK Parkinson's Disease Society, Brain Bank and PD-MCI in accordance with the diagnostic criteria suggestions by Litvan;
  • Diagnosed with aMCI based on diagnosis criteria (CDR\>0.5) suggested by Petersen;
  • On a stable pharmacological treatment minimum for one month with no washout period.

You're excluded if

  • Illiterate or education level less than primary school
  • Having an existing and/or prior neurological disease; psychiatric disease or head trauma; and/or irreversible hearing or sight problems or other medical illness (e.g. diabetes mellitus, hypertension);
  • Exhibiting signs of dementia for PD group ;
  • Having medical issues that prevent undergoing fMRI or for tDCS application.

The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.

Eligibility criteria as of 2025-05-02

View full record on ClinicalTrials.gov

All APOE4 clinical trials